Drug intelligence / Profile preview

GSK2339345

Development stage: Phase 2
Lead developer: GSK
Modality: Small Molecules
Administration: Inhalation

Overview

GSK2339345 is an investigational inhaled small molecule developed by GSK as a voltage-gated sodium channel (VGSC) blocker for the treatment of chronic cough, specifically refractory or chronic idiopathic cough. Its mechanism of action involves antagonism of sodium channels in airway sensory nerves, aiming to reduce cough reflex sensitivity. Clinical studies showed that while the drug reached airway sensory nerves and was well tolerated, it did not demonstrate anti-tussive efficacy compared to placebo. Development for this indication has been discontinued[2][4][5].

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on GSK2339345.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2339345.

Explore the full profile